Walter J. Malinowski

Array ( [id] => 14581399 [patent_doc_number] => 20190218308 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-07-18 [patent_title] => RESTORATION OF T CELL ACTIVITY VIA THE CD39/CD73 AXIS [patent_app_type] => utility [patent_app_number] => 16/370726 [patent_app_country] => US [patent_app_date] => 2019-03-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 44248 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -30 [patent_words_short_claim] => 42 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16370726 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14564189 [patent_doc_number] => 20190209701 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-07-11 [patent_title] => COMBINATION THERAPY WITH A MEK INHIBITOR, A PD-1 AXIS INHIBITOR, AND A TAXANE [patent_app_type] => utility [patent_app_number] => 16/366411 [patent_app_country] => US [patent_app_date] => 2019-03-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19453 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -30 [patent_words_short_claim] => 48 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16366411 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14534617 [patent_doc_number] => 20190202930 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-07-04 [patent_title] => METHODS FOR TREATMENT OF OVARIAN CANCER [patent_app_type] => utility [patent_app_number] => 16/357577 [patent_app_country] => US [patent_app_date] => 2019-03-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20453 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -39 [patent_words_short_claim] => 73 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16357577 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14534613 [patent_doc_number] => 20190202928 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-07-04 [patent_title] => Humanized Anti-CD134 (OX40) Antibodies And Uses Thereof [patent_app_type] => utility [patent_app_number] => 16/351852 [patent_app_country] => US [patent_app_date] => 2019-03-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 44625 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16351852 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16526595 [patent_doc_number] => 20200400675 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-12-24 [patent_title] => PROGASTRIN AS A BIOMARKER FOR IMMUNOTHERAPY [patent_app_type] => utility [patent_app_number] => 16/975271 [patent_app_country] => US [patent_app_date] => 2019-02-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26672 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 60 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16975271 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16614970 [patent_doc_number] => 20210033623 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-02-04 [patent_title] => TISSUE ANALYSIS BY MASS SPECTROMETRY [patent_app_type] => utility [patent_app_number] => 16/971992 [patent_app_country] => US [patent_app_date] => 2019-02-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9444 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -35 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16971992 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14833493 [patent_doc_number] => 20190275147 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-09-12 [patent_title] => ANTITUMOUR COMBINATIONS CONTAINING A VEGF INHIBITING AGENT AND IRINOTECAN [patent_app_type] => utility [patent_app_number] => 16/272315 [patent_app_country] => US [patent_app_date] => 2019-02-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 2792 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 9 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16272315 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14403693 [patent_doc_number] => 20190167690 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-06-06 [patent_title] => Immuno-Gene Combination Therapy [patent_app_type] => utility [patent_app_number] => 16/268548 [patent_app_country] => US [patent_app_date] => 2019-02-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10480 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 92 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16268548 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16948164 [patent_doc_number] => 20210206855 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-07-08 [patent_title] => ANTI-CTLA4 ANTIBODIES AND METHODS OF MAKING AND USING THE SAME [patent_app_type] => utility [patent_app_number] => 16/966844 [patent_app_country] => US [patent_app_date] => 2019-02-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 58823 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16966844 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17769403 [patent_doc_number] => 11401331 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-08-02 [patent_title] => Anti-PD-L1 antibody and IL-7 fusions [patent_app_type] => utility [patent_app_number] => 16/482023 [patent_app_country] => US [patent_app_date] => 2019-01-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 14 [patent_no_of_words] => 13032 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 29 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16482023 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14583945 [patent_doc_number] => 20190219581 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-07-18 [patent_title] => METHOD FOR PREDICTING THE RESPONSE TO HER2-DIRECTED THERAPY [patent_app_type] => utility [patent_app_number] => 16/252424 [patent_app_country] => US [patent_app_date] => 2019-01-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11133 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -4 [patent_words_short_claim] => 63 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16252424 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14583949 [patent_doc_number] => 20190219583 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-07-18 [patent_title] => METHODS FOR DIAGNOSING PANCREATIC CANCER [patent_app_type] => utility [patent_app_number] => 16/251213 [patent_app_country] => US [patent_app_date] => 2019-01-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30942 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16251213 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14277319 [patent_doc_number] => 20190135944 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-05-09 [patent_title] => CELL BASED ANTI-CANCER COMPOSITIONS WITH REDUCED TOXICITY AND METHODS OF MAKING THE SAME [patent_app_type] => utility [patent_app_number] => 16/236249 [patent_app_country] => US [patent_app_date] => 2018-12-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23684 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16236249 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17527889 [patent_doc_number] => 11300569 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-04-12 [patent_title] => In vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method [patent_app_type] => utility [patent_app_number] => 16/220014 [patent_app_country] => US [patent_app_date] => 2018-12-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 26 [patent_no_of_words] => 42133 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 186 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16220014 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14158811 [patent_doc_number] => 20190106508 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-04-11 [patent_title] => ANTIBODIES THAT BIND CELL-ASSOCIATED CA 125/O772P [patent_app_type] => utility [patent_app_number] => 16/219408 [patent_app_country] => US [patent_app_date] => 2018-12-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 39634 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 110 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16219408 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14185933 [patent_doc_number] => 20190112671 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-04-18 [patent_title] => Breast Cancer Immunotherapy and Methods [patent_app_type] => utility [patent_app_number] => 16/205871 [patent_app_country] => US [patent_app_date] => 2018-11-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13438 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 70 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16205871 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14072373 [patent_doc_number] => 20190085074 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-03-21 [patent_title] => Antibodies Towards an Extracellular Region of NBCn1 [patent_app_type] => utility [patent_app_number] => 16/205618 [patent_app_country] => US [patent_app_date] => 2018-11-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24664 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 40 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16205618 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18933398 [patent_doc_number] => 11885815 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-01-30 [patent_title] => Reducing junction epitope presentation for neoantigens [patent_app_type] => utility [patent_app_number] => 16/766627 [patent_app_country] => US [patent_app_date] => 2018-11-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 23 [patent_no_of_words] => 40194 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 366 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16766627 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16114435 [patent_doc_number] => 20200209240 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-07-02 [patent_title] => CD19CART CELLS ELIMINATE MYELOMA CELLS THAT EXPRESS VERY LOW LEVELS OF CD19 [patent_app_type] => utility [patent_app_number] => 16/646986 [patent_app_country] => US [patent_app_date] => 2018-11-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15333 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -123 [patent_words_short_claim] => 43 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16646986 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14016595 [patent_doc_number] => 20190070291 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-03-07 [patent_title] => GENE DETECTION ASSAY FOR IMPROVING THE LIKELIHOOD OF AN EFFECTIVE RESPONSE TO AN ErbB ANTAGONIST CANCER THERAPY [patent_app_type] => utility [patent_app_number] => 16/182971 [patent_app_country] => US [patent_app_date] => 2018-11-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10972 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16182971 [rel_patent_id] =>[rel_patent_doc_number] =>)